Board of Directors

Mark J. Alles

Mark J. Alles serves as Celgene Corporation’s Chairman and Chief Executive Officer. He assumed the role of Chief Executive Officer and joined the Celgene Board of Directors on March 1, 2016. The role of Chairman was added on February 6, 2018.

Mr. Alles served as President and Chief Operating Officer from August 2014 until February 2016, Executive Vice President and Global Head of Hematology and Oncology from December 2012 until July 2014, and was also Celgene’s Chief Commercial Officer. Mr. Alles joined Celgene in April 2004 and was Vice President, Global Hematology Marketing until March 2009 when he was promoted to President of the Americas Region. Responsibility for commercial operations in Japan and the Asia Pacific Region was added in July 2011. Before joining Celgene, he was Vice President of the U.S. Oncology business unit at Aventis Pharmaceuticals and served in other senior commercial management roles at Aventis (Rhône-Poulenc Rorer) from 1993-2004.

After earning his B.S. degree from Lock Haven University of Pennsylvania and serving as a Captain in the United States Marine Corps, Mr. Alles began his thirty-year career in the pharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson. He is a member of the Board of Directors of the Pharmaceutical Manufacturers of America (PhRMA), the European Federation of the Pharmaceutical Industries and Associations (EFPIA), and serves on the Board of Gilda’s Club NYC, a non-profit organization dedicated to helping families of people living with cancer.

Chair of the Executive Committee
Recent Stock Transactions by Mark J. Alles
Date Type Shares Traded Price Range
May 9, 2018 Buy 1,208 82.60
May 4, 2018 Disposition (Non Open Market) 1,519 86.89
May 4, 2018 Option Execute 3,500 n/a
Feb 17, 2018 Disposition (Non Open Market) 2,060 95.26
Feb 17, 2018 Option Execute 7,283 n/a
Feb 8, 2018 Buy 3,260 91.90
Dec 19, 2017 Disposition (Non Open Market) 2,094 107.06
Dec 19, 2017 Option Execute 4,550 n/a
Jul 28, 2017 Disposition (Non Open Market) 1,932 134.10
Jul 28, 2017 Option Execute 4,200 n/a
Feb 14, 2017 Acquisition (Non Open Market) 14,447 n/a
Feb 14, 2017 Disposition (Non Open Market) 6,643 117.02
Dec 2, 2016 Disposition (Non Open Market) 3,018 117.63
Dec 2, 2016 Option Execute 6,560 n/a
Apr 29, 2016 Disposition (Non Open Market) 5,062 103.41
Apr 29, 2016 Option Execute 11,000 n/a
Feb 12, 2016 Acquisition (Non Open Market) 25,840 n/a
Feb 12, 2016 Disposition (Non Open Market) 11,889 102.45
Jan 29, 2016 Option Execute 21,938 19.24 - 36.96
Dec 17, 2015 Disposition (Non Open Market) 5,370 112.17
Dec 17, 2015 Option Execute 11,670 n/a
Apr 30, 2015 Disposition (Non Open Market) 5,154 108.06
Apr 30, 2015 Option Execute 11,200 n/a
Mar 1, 2015 Disposition (Non Open Market) 4,078 121.53
Mar 1, 2015 Option Execute 8,334 n/a
Feb 12, 2015 Option Execute 27,505 25.77 - 81.56
Feb 6, 2015 Automatic Sell 117,099 120.68
Feb 6, 2015 Acquisition (Non Open Market) 30,404 n/a
Feb 6, 2015 Disposition (Non Open Market) 13,666 118.75
Feb 6, 2015 Option Execute 107,859 25.77 - 81.56
Feb 12, 2014 Acquisition (Non Open Market) 15,188 n/a
Feb 12, 2014 Disposition (Non Open Market) 6,837 160.54
Dec 27, 2013 Disposition (Non Open Market) 3,501 168.93
Dec 27, 2013 Option Execute 7,777 n/a
Nov 1, 2013 Disposition (Non Open Market) 4,502 151.31
Nov 1, 2013 Option Execute 10,000 n/a
Aug 2, 2013 Sell 5,000 146.47
Aug 2, 2013 Option Execute 15,000 62.35 - 70.63
Jul 31, 2013 Sell 96,406 147.01
Jul 31, 2013 Option Execute 96,406 38.47 - 73.92
Apr 13, 2013 Disposition (Non Open Market) 1,791 123.00
Apr 13, 2013 Option Execute 4,583 n/a
Apr 14, 2012 Disposition (Non Open Market) 902 78.32
Apr 14, 2012 Option Execute 3,056 n/a
Feb 15, 2012 Statement of Ownership 0 n/a
Richard W. Barker, D.Phil. OBE

Richard W. Barker, D.Phil., OBE, was elected to the Celgene Board of Directors in January 2012 and is a member of the Audit Committee.

Dr. Barker was formerly Director General of the Association of the British Pharmaceutical Industry (ABPI), a pharmaceutical industry trade association in the United Kingdom, from 2004 to 2011, and served on the Board and Executive Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and as a Council Member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). Dr. Barker is currently Director of the Centre for the Advancement of Medical Innovations (CASMI), Director of Precision Medicine PLC, a UK government research entity, Chairman of the Health Innovation Network of South London, UK, Chairman of International Health Partners, a UK charity providing donated medicines to crisis situations, and Chairman of Image Analysis Group, a company applying advanced algorithmic analysis to medical images.

Recent Stock Transactions by Richard W. Barker, D.Phil. OBE
Date Type Shares Traded Price Range
Jun 17, 2018 Disposition (Non Open Market) 298 78.08
Jun 17, 2018 Option Execute 1,000 n/a
Jul 1, 2017 Disposition (Non Open Market) 220 129.87
Jul 1, 2017 Option Execute 734 n/a
Sep 23, 2016 Sell 20,000 110.82
Sep 23, 2016 Option Execute 20,000 36.92
Jul 1, 2016 Disposition (Non Open Market) 219 100.70
Jul 1, 2016 Option Execute 733 n/a
Jun 12, 2016 Disposition (Non Open Market) 620 102.91
Jun 12, 2016 Option Execute 2,068 n/a
Jul 1, 2015 Disposition (Non Open Market) 219 118.22
Jul 1, 2015 Option Execute 733 n/a
Jun 13, 2015 Disposition (Non Open Market) 620 111.32
Jun 13, 2015 Option Execute 2,068 n/a
Jun 12, 2015 Disposition (Non Open Market) 619 111.32
Jun 12, 2015 Option Execute 2,066 n/a
Jul 25, 2014 Sell 17,600 87.03
Jul 25, 2014 Option Execute 18,600 31.80
Jun 13, 2014 Disposition (Non Open Market) 309 159.99
Jun 13, 2014 Option Execute 1,033 n/a
Jun 12, 2014 Disposition (Non Open Market) 309 160.22
Jun 12, 2014 Option Execute 1,033 n/a
Jun 13, 2013 Option Execute 1,033 n/a
Hans Bishop

Hans Bishop was elected to the Celgene Board of Directors in April 2018.

Mr. Bishop co-founded Juno Therapeutics in 2013 and served as President and CEO until Juno was acquired by Celgene in March 2018. He served as an Executive in Residence at Warburg Pincus, a global private equity firm with significant investment experience in the pharmaceutical and healthcare industries. Prior to this, he acted as Executive Vice President and Chief Operating Officer for Dendreon, a Seattle-based biotechnology company that develops immunotherapy products used in cancer treatment. He has served as President of Specialty Medicine at Bayer Healthcare, Senior Vice President of Global Commercial Operations at Chiron Corporation, and Vice President and General Manager of European Biopharmaceuticals. Mr. Bishop previously held various positions at Glaxo Wellcome and SmithKlineBeecham. Mr. Bishop earned a B.S. in chemistry from Brunel University in London.

Michael W. Bonney

Michael W. Bonney was elected to the Celgene Board of Directors in April 2015. Mr. Bonney is a member of the Executive Committee and the Nominating, Governance and Compliance Committee.

Mr. Bonney is currently the CEO and Chairman of the Board of Kaleido Biosciences, Inc. From January to July 2016, Mr. Bonney was a Partner of Third Rock Ventures, LLC. Prior thereto, Mr. Bonney served as Chief Executive Officer and a member of the Board of Directors of Cubist Pharmaceuticals Inc. (a subsidiary of Merck & Co., Inc. as of January 2015) from June 2003 until his retirement in 2014. From 2002 to 2003, Mr. Bonney served as Cubist’s President and Chief Operating Officer, and from 1995 to 2001, he held various positions of increasing responsibility at Biogen, Inc., including Vice President, Sales and Marketing from 1999 to 2001. Prior to joining Biogen, Mr. Bonney held various positions of increasing responsibility in sales, marketing and strategic planning at Zeneca Pharmaceuticals. Mr. Bonney is Chairman of the Board of Directors of Alnylam Pharmaceuticals, Inc. He is also a Trustee of the Tekla complex of life sciences and healthcare dedicated funds. Mr. Bonney received a B.A. in Economics from Bates College and now Chairs its Board of Trustees.

Member of the Executive Committee
Michael D. Casey

Michael D. Casey was elected to the Celgene Board of Directors in August 2002 and has been the Lead Independent Director since June 2007. Mr. Casey is the Chairman of the Nominating, Governance and Compliance Committee, a member of the Executive Committee, and a member of the Compensation and Development Committee.

From September 1997 to February 2002, Mr. Casey served as the Chairman, President, Chief Executive Officer and a director of Matrix Pharmaceutical, Inc. From November 1995 to September 1997, Mr. Casey was Executive Vice President at Schein Pharmaceutical, Inc. In December 1996, he was appointed President of the retail and specialty products division of Schein Pharmaceutical, Inc. From June 1993 to November 1995, he served as President and Chief Operating Officer of Genetic Therapy, Inc. Mr. Casey was President of McNeil Pharmaceutical (a unit of Johnson & Johnson) from 1989 to June 1993 and Vice President, Sales and Marketing for Ortho Pharmaceutical Corp. (a subsidiary of Johnson & Johnson) from 1985 to 1989. Mr. Casey is also a director of Abaxis Inc.

Member of the Executive Committee
Recent Stock Transactions by Michael D. Casey
Date Type Shares Traded Price Range
Jun 17, 2018 Option Execute 334 n/a
Jun 15, 2018 Option Execute 375 n/a
Jun 14, 2018 Option Execute 300 n/a
Jun 7, 2018 Sell 13,000 78.77
Jun 7, 2018 Option Execute 27,750 30.01
Feb 28, 2018 Option Execute 9,250 27.18
Sep 5, 2017 Acquisition (Non Open Market) 9,250 24.97
Sep 5, 2017 Sell 9,250 139.03
Jul 1, 2017 Option Execute 734 n/a
Jun 21, 2017 Sell 9,250 133.05
Jun 21, 2017 Option Execute 9,250 33.88
Jun 19, 2017 Sell 9,250 125.59
Jun 17, 2017 Option Execute 333 n/a
Jun 15, 2017 Option Execute 375 n/a
May 30, 2017 Option Execute 9,250 28.97
Feb 27, 2017 Sell 7,500 121.55
Feb 27, 2017 Option Execute 7,500 25.58
Jan 12, 2017 Disposition (Non Open Market) 84 n/a
Jan 11, 2017 Disposition (Non Open Market) 84 n/a
Dec 23, 2016 Disposition (Non Open Market) 593 n/a
Oct 18, 2016 Option Execute 7,500 100.06
Aug 22, 2016 Sell 43,134 114.01
Jul 1, 2016 Option Execute 733 n/a
Jun 17, 2016 Option Execute 333 n/a
Jun 12, 2016 Option Execute 2,068 n/a
Dec 23, 2015 Sell 20,000 122.11
Dec 21, 2015 Option Execute 60,000 110.84
Sep 8, 2015 Sell 15,000 121.76
Sep 8, 2015 Option Execute 15,000 14.25
Jul 1, 2015 Option Execute 733 n/a
Jun 13, 2015 Option Execute 2,068 n/a
Jun 12, 2015 Option Execute 2,066 n/a
Jun 9, 2015 Sell 1,800 110.50
Jun 9, 2015 Option Execute 1,800 9.93
Jun 8, 2015 Sell 13,200 111.27
Jun 8, 2015 Option Execute 13,200 9.93
Feb 25, 2015 Sell 15,000 123.19
Feb 25, 2015 Option Execute 15,000 8.47
Oct 24, 2014 Sell 15,000 102.94
Oct 24, 2014 Option Execute 15,000 7.09
Aug 14, 2014 Sell 30,000 88.59
Aug 14, 2014 Option Execute 30,000 7.25
Jun 16, 2014 Disposition (Non Open Market) 3,100 n/a
Jun 15, 2014 Option Execute 1,034 n/a
Jun 13, 2014 Option Execute 1,033 n/a
Jun 12, 2014 Option Execute 1,033 n/a
Jun 9, 2014 Disposition (Non Open Market) 15,000 n/a
Jun 9, 2014 Option Execute 15,000 13.68
Mar 4, 2014 Sell 12,770 162.33
Mar 4, 2014 Option Execute 12,770 10.97
Carrie S. Cox

Carrie S. Cox was elected to the Celgene Board of Directors in December 2009 and is a member of the Compensation and Development Committee.

Ms. Cox currently serves as the Chairman of the Board of Directors and Chief Executive Officer of Humacyte, Inc., a privately-held regenerative medicine company primarily focused on developing novel human tissue-based investigational products for applications in regenerative medicine and vascular surgery. Ms. Cox served as Executive Vice President of Schering-Plough and President of Schering-Plough’s Global Pharmaceutical Business until 2009 when Schering-Plough merged with Merck & Co., Inc. Prior to joining Schering-Plough, Ms. Cox served as President of Pharmacia Corporation’s pharmaceutical business until its merger with Pfizer Inc. in 2003. Ms. Cox is a member of the Board of Directors of Texas Instruments and Cardinal Health, Inc. Ms. Cox is a graduate of the Massachusetts College of Pharmacy.

Recent Stock Transactions by Carrie S. Cox
Date Type Shares Traded Price Range
Jun 12, 2018 Option Execute 6,200 n/a
Jul 1, 2017 Option Execute 734 n/a
Jul 1, 2016 Option Execute 733 n/a
Jun 16, 2016 Option Execute 6,200 n/a
Jul 1, 2015 Option Execute 733 n/a
Jun 16, 2015 Option Execute 2,050 n/a
Oct 25, 2013 Sell 18,750 157.67
Oct 25, 2013 Option Execute 24,900 51.78 - 55.38
Michael A. Friedman, M.D.

Michael A. Friedman, M.D., was elected to the Celgene Board of Directors in February 2011 and is a member of the Nominating, Governance and Compliance Committee.

Dr. Friedman is the emeritus Chief Executive Officer of City of Hope, a leading cancer research, treatment and education institution, as well as Director of the organization’s Comprehensive Cancer Center and holder of the Irell & Manella Cancer Center Director’s Distinguished Chair. Before leading City of Hope, Dr. Friedman was Senior Vice President of Research and Development, Medical and Public Policy for Pharmacia Corporation and Chief Medical Officer for biomedical preparedness at PhRMA. Additionally, Dr. Friedman has served as Deputy Commissioner for the U.S. Food and Drug Administration (FDA), later serving as Acting Commissioner, and as Associate Director of the National Cancer Institute, National Institutes of Health. Since 2004, Dr. Friedman has served on the Independent Citizens’ Oversight Committee which governs the California Institute for Regenerative Medicine and oversees the implementation of California’s stem cell research effort. Dr. Friedman is a member of the Board of Directors of MannKind Corporation, Smith & Nephew plc. and Intuitive Surgical, Inc. He is also a member of the Board of Trustees of Tulane University.

Recent Stock Transactions by Michael A. Friedman, M.D.
Date Type Shares Traded Price Range
Jun 17, 2018 Option Execute 334 n/a
Jun 15, 2018 Option Execute 2,413 n/a
Jun 14, 2018 Option Execute 300 n/a
Jul 1, 2017 Option Execute 734 n/a
Jun 22, 2017 Automatic Sell 5,000 135.00
Jun 22, 2017 Option Execute 5,000 59.06
Jun 21, 2017 Automatic Sell 5,000 130.00
Jun 21, 2017 Option Execute 5,000 59.06
Jun 19, 2017 Automatic Sell 5,000 125.00
Jun 19, 2017 Option Execute 5,000 59.06
Jun 17, 2017 Option Execute 333 n/a
Jun 15, 2017 Option Execute 375 n/a
Nov 9, 2016 Automatic Sell 18,600 116.10
Nov 9, 2016 Option Execute 18,600 31.80
Oct 3, 2016 Automatic Sell 56,116 103.66
Oct 3, 2016 Option Execute 56,116 29.00 - 29.96
Jul 1, 2016 Option Execute 733 n/a
Jun 17, 2016 Option Execute 333 n/a
Jun 12, 2016 Option Execute 2,068 n/a
Jul 1, 2015 Option Execute 733 n/a
Jun 13, 2015 Option Execute 2,068 n/a
Jun 12, 2015 Option Execute 2,066 n/a
Jun 13, 2014 Option Execute 1,033 n/a
Jun 12, 2014 Option Execute 1,033 n/a
Jun 13, 2013 Option Execute 1,033 n/a
Julia A. Haller, M.D

Julia Haller, M.D., was elected to the Celgene Board of Directors in October 2015 and is a member of the Audit Committee.

Dr. Haller is Ophthalmologist-in-Chief of the Wills Eye Hospital in Philadelphia, where she holds the William Tasman, M.D. Endowed Chair. She serves as Professor and Chair of the Department of Ophthalmology at Jefferson Medical College of Thomas Jefferson University and Thomas Jefferson University Hospitals, and is Co-Director of the Wills Vision Research Center at Jefferson. In 1986, Dr. Haller served as the first female Chief Resident at the Wilmer Eye Institute at Johns Hopkins and later joined the Johns Hopkins faculty. She was named the inaugural Katharine Graham Professor of Ophthalmology in 2002, and the inaugural Robert Bond Welch, M.D. Professor of Ophthalmology in 2006. In 2007, Dr. Haller assumed leadership of Wills Eye Hospital. She received her A.B. from Princeton University magna cum laude and her M.D. from Harvard Medical School.

Patricia Hemingway Hall

Patricia “Pat” Hemingway Hall was elected to the Celgene Board of Directors in April 2018 and is a member of the Audit Committee.

Ms. Hemingway Hall has more than 30 years of experience with a focus on the US health insurance market. Ms. Hemingway Hall retired as CEO of Health Care Service Corporation (HCSC), the nation’s largest mutual health insurance company, which operates as Blue Cross and Blue Shield in Illinois, Montana, New Mexico, Oklahoma and Texas, in 2015. Previously, Ms. Hemingway Hall served as President and Chief Operating Officer of HCSC and as President of Blue Cross and Blue Shield of Texas (BCBSTX). Prior to joining HCSC in 1993, she held positions at A. Foster Higgins, Aetna/Partners Health Plans, VHA and Blue Cross and Blue Shield of Florida. Ms. Hemingway Hall currently serves on the boards of directors of Manpower Group and Cardinal Health. She earned a Master’s in Public Health, health planning and administration from the University of Michigan and a Bachelor of Science in nursing from Michigan State University.

Gilla Kaplan Ph.D.

Gilla Kaplan, Ph.D., was elected to the Celgene Board of Directors in April 1998.

Dr. Kaplan was appointed Director of the Global Health Program, Tuberculosis, at the Bill and Melinda Gates Foundation in January 2014. She previously served as Senior Advisor to the Global Health Program, Tuberculosis and member of the International Scientific Advisory Committee for the Global Health Program of the Bill and Melinda Gates Foundation. Dr. Kaplan was head of the Laboratory of Mycobacterial Immunity and Pathogenesis at The Public Health Research Institute Center at the New Jersey Medical School, Newark, New Jersey, where she was appointed full Member in 2002 and Assistant Director in 2006. Dr. Kaplan also was previously appointed, in 2005, Professor of Medicine at the University of Medicine and Dentistry of New Jersey. Prior to that, Dr. Kaplan was an immunologist in the Laboratory at Cellular Physiology and Immunology at The Rockefeller University in New York where she was an Associate Professor.

Recent Stock Transactions by Gilla Kaplan Ph.D.
Date Type Shares Traded Price Range
May 18, 2018 Sell 27,750 78.66
May 18, 2018 Option Execute 27,750 30.01
Feb 20, 2018 Sell 9,250 94.83
Feb 15, 2018 Sell 9,250 95.99
Feb 15, 2018 Option Execute 9,250 27.18
Dec 5, 2017 Option Execute 9,250 24.97
Sep 12, 2017 Sell 9,250 141.56
Sep 12, 2017 Option Execute 9,250 33.88
Aug 2, 2017 Sell 7,500 134.52
Jul 1, 2017 Option Execute 734 n/a
Jun 17, 2017 Option Execute 333 n/a
Jun 15, 2017 Option Execute 375 n/a
Jun 1, 2017 Option Execute 9,250 28.97
Mar 30, 2017 Sell 14,033 123.83
Mar 3, 2017 Option Execute 7,500 25.58
Sep 19, 2016 Option Execute 7,500 29.26
Sep 15, 2016 Sell 9,710 106.44
Jul 1, 2016 Option Execute 733 n/a
Jun 17, 2016 Option Execute 333 n/a
Jun 15, 2016 Option Execute 6,200 n/a
Jun 12, 2016 Option Execute 2,068 n/a
Apr 4, 2016 Automatic Sell 15,967 101.84
Dec 21, 2015 Automatic Sell 14,464 110.62
Dec 21, 2015 Option Execute 14,464 16.21
Sep 10, 2015 Sell 15,000 122.45
Sep 10, 2015 Option Execute 15,000 14.25
Jul 1, 2015 Option Execute 733 n/a
Jun 16, 2015 Option Execute 4,110 n/a
Jun 13, 2015 Option Execute 2,068 n/a
Jun 12, 2015 Option Execute 2,066 n/a
Jun 10, 2015 Sell 15,000 111.74
Jun 10, 2015 Option Execute 15,000 9.93
Feb 26, 2015 Sell 15,000 122.89
Feb 26, 2015 Option Execute 15,000 8.47
Jan 2, 2015 Automatic Sell 45,536 113.47
Jan 2, 2015 Option Execute 45,536 16.21
Dec 8, 2014 Automatic Sell 15,000 118.20
Dec 8, 2014 Option Execute 15,000 7.09
Sep 8, 2014 Automatic Sell 30,000 93.73
Sep 8, 2014 Option Execute 30,000 7.25
Jun 13, 2014 Option Execute 1,033 n/a
Jun 12, 2014 Option Execute 1,033 n/a
Jun 9, 2014 Automatic Sell 15,000 161.62
Jun 9, 2014 Option Execute 15,000 13.68
Feb 13, 2014 Option Execute 15,000 10.97
Dec 9, 2013 Automatic Sell 15,000 172.17
Dec 9, 2013 Option Execute 15,000 11.21
Sep 4, 2013 Automatic Sell 15,000 143.92
Sep 4, 2013 Option Execute 15,000 11.23
Jun 13, 2013 Option Execute 1,033 n/a
James J. Loughlin

James J. Loughlin was elected to the Celgene Board of Directors in January 2007. Mr. Loughlin is Chairman of the Audit Committee and a member of the Compensation and Development Committee.

Mr. Loughlin served as the National Director of the Pharmaceuticals Practice at KPMG LLP (KPMG), and a five-year term as member of the Board of Directors of KPMG. Additionally, Mr. Loughlin served as Chairman of the Pension and Investment Committee of the KPMG Board from 1995 through 2001. He also served as Partner in charge of Human Resources, Chairman of the Personnel and Professional Development Committee, Secretary and Trustee of the Peat Marwick Foundation and a member of the Pension, Operating and Strategic Planning Committees. Mr. Loughlin serves as a member of the Board of Directors of Edge Therapeutics, Inc.

Recent Stock Transactions by James J. Loughlin
Date Type Shares Traded Price Range
Jun 17, 2018 Option Execute 334 n/a
Jun 15, 2018 Option Execute 2,441 n/a
Jun 14, 2018 Option Execute 300 n/a
Jun 4, 2018 Sell 17,750 78.96
Jun 4, 2018 Option Execute 27,750 30.01
Mar 12, 2018 Sell 9,250 92.01
Mar 12, 2018 Option Execute 9,250 27.18
Jul 1, 2017 Option Execute 734 n/a
Jun 26, 2017 Automatic Sell 18,500 133.57
Jun 26, 2017 Option Execute 18,500 24.97 - 33.88
Jun 17, 2017 Option Execute 333 n/a
Jun 15, 2017 Option Execute 375 n/a
May 1, 2017 Sell 9,250 124.00
May 1, 2017 Option Execute 9,250 28.96
Aug 23, 2016 Sell 27,500 114.10
Aug 23, 2016 Option Execute 27,500 25.58 - 26.65
Jul 1, 2016 Option Execute 733 n/a
Jun 17, 2016 Option Execute 333 n/a
Jun 12, 2016 Option Execute 2,068 n/a
Feb 22, 2016 Sell 2,100 104.12
Jul 1, 2015 Option Execute 733 n/a
Jun 13, 2015 Option Execute 2,068 n/a
Jun 12, 2015 Option Execute 2,066 n/a
Aug 22, 2014 Sell 20,000 91.25
Aug 22, 2014 Option Execute 20,000 28.65
Jun 13, 2014 Option Execute 1,033 n/a
Jun 12, 2014 Option Execute 1,033 n/a
Jun 16, 2013 Option Execute 685 n/a
Jun 13, 2013 Option Execute 1,033 n/a
Jun 22, 2012 Buy 600 60.29
Jun 17, 2012 Option Execute 685 n/a
Jun 16, 2012 Option Execute 685 n/a
Jun 17, 2011 Option Execute 685 n/a
Jun 16, 2011 Option Execute 685 n/a
Ernest Mario, Ph.D.

Ernest Mario, Ph.D . was elected to the Celgene Board of Directors in August 2007. Dr. Mario is Chairman of the Compensation and Development Committee, a member of the Nominating, Governance and Compliance Committee, and a member of the Executive Committee.

Dr. Mario is a former Deputy Chairman and Chief Executive of Glaxo Holdings plc and a former Chairman and Chief Executive Officer of ALZA Corporation. Dr. Mario currently is the Chairman of Capnia, Inc., a privately-held specialty pharmaceutical company in Palo Alto, California. Dr. Mario serves as a member of the Board of Directors for Boston Scientific Corporation, Kindred Biosciences Inc., XenoPort Inc. and Tonix Pharmaceuticals Holding Corp. He is Chairman of the American Foundation for Pharmaceutical Education and serves as an advisor to The Ernest Mario School of Pharmacy at Rutgers University. In 2007, Dr. Mario was awarded the Remington Medal by the American Pharmacists Association, pharmacy’s highest honor.

Member of the Executive Committee
Recent Stock Transactions by Ernest Mario, Ph.D.
Date Type Shares Traded Price Range
Jun 17, 2018 Option Execute 334 n/a
Jun 15, 2018 Option Execute 375 n/a
Jun 14, 2018 Option Execute 300 n/a
Feb 23, 2018 Sell 13,370 94.49
Feb 14, 2018 Disposition (Non Open Market) 2,250 n/a
Feb 14, 2018 Disposition (Non Open Market) 2,250 n/a
Oct 30, 2017 Option Execute 13,600 31.80
Aug 10, 2017 Sell 18,506 130.52
Jul 1, 2017 Option Execute 734 n/a
Jun 17, 2017 Option Execute 333 n/a
Jun 15, 2017 Option Execute 375 n/a
Feb 27, 2017 Sell 12,000 121.24
Feb 1, 2017 Disposition (Non Open Market) 3,570 n/a
Sep 23, 2016 Sell 15,000 109.42
Jul 1, 2016 Option Execute 733 n/a
Jun 17, 2016 Option Execute 333 n/a
Jun 16, 2016 Option Execute 2,055 n/a
Jun 12, 2016 Option Execute 2,068 n/a
Apr 26, 2016 Option Execute 5,000 31.80
Feb 1, 2016 Option Execute 18,600 29.00
Dec 28, 2015 Sell 40,000 119.36
Jul 31, 2015 Sell 19,442 131.73
Jul 1, 2015 Option Execute 733 n/a
Jun 13, 2015 Option Execute 2,068 n/a
Jun 12, 2015 Option Execute 2,066 n/a
Feb 3, 2015 Option Execute 7,666 27.69
Oct 27, 2014 Sell 100,000 102.85
Jul 24, 2014 Option Execute 5,000 27.69
Jun 15, 2014 Option Execute 3,100 n/a
Jun 13, 2014 Option Execute 1,033 n/a
Jun 12, 2014 Option Execute 1,033 n/a
Apr 7, 2014 Option Execute 6,000 55.38
Mar 25, 2014 Disposition (Non Open Market) 196 n/a
Mar 25, 2014 Disposition (Non Open Market) 196 n/a
Mar 3, 2014 Disposition (Non Open Market) 2,210 n/a
Mar 3, 2014 Disposition (Non Open Market) 2,210 n/a
Feb 18, 2014 Disposition (Non Open Market) 1,020 n/a
Feb 18, 2014 Disposition (Non Open Market) 1,020 n/a
Feb 5, 2014 Sell 13,500 151.87
Feb 5, 2014 Option Execute 13,500 59.89 - 67.75
Feb 4, 2014 Option Execute 7,000 60.02
Jan 7, 2014 Option Execute 2,000 59.89
Oct 24, 2013 Option Execute 6,000 59.89
Aug 14, 2013 Option Execute 4,625 54.35
Jun 13, 2013 Option Execute 1,033 n/a
Jun 5, 2013 Option Execute 15,000 59.89
May 29, 2013 Buy 1,000 123.72 - 123.73
Jun 17, 2012 Option Execute 685 n/a
Apr 27, 2012 Option Execute 16,958 44.94 - 49.93
Dec 5, 2011 Buy 2,000 61.30 - 61.40
John H. Weiland

John Weiland was elected to the Celgene Board of Directors in February 2018 and is a member of the Audit Committee.

Mr. Weiland was President and Chief Operating Officer of C. R. Bard, Inc. from 1996 until his retirement in 2017 when C.R. Bard was acquired by Becton Dickinson. He was elected to Bard’s Board of Directors in 2005 and became Vice Chairman of the Board in 2016. Prior to becoming President and COO, he held the position of Group President. Prior to Bard, Mr. Weiland held the position of Senior Vice President North America Group for Dentsply International. Mr. Weiland started his career at Baxter/American Hospital Supply Corporation in 1977. He rose through numerous managerial positions to become Vice President and General Manager of the Scientific Products Biomedical Division. In 1989, he became President and Chief Executive Officer of Pharmacia Diagnostics, a division of Pharmacia AB Uppsala Sweden. In addition to his professional activities, John is actively involved in civic affairs. In 2012, John was the recipient of the distinguished Horatio Alger Award. He is a member of the Board of Directors of West Pharmaceutical Services, Inc. and the Horatio Alger Association. Mr. Weiland graduated from DeSales University with a B.S. degree and earned an M.B.A. degree from New York University.

Stock transaction information provided by EDGAR Online. Celgene Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.